1、6月迎来多个药物审批事件,哪些公司值得配置?
2、$Cogent Biosciences(COGT)、$Day One(DAWN)、$莱斯康制药(LXRX)等多家医药公司增发,哪些公司有配置机会?
3、$斯普林特(S)、$台积电(TSM)$ 、$创新ETF-ARK(ARKK)$ 、$中概互联网指数ETF-KraneShares(...查看全文
Cogent Biosciences(COGT)04-13 04:35
$Cogent Biosciences(COGT)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-094760 Act: 34 Size: 728 KB 网页链接查看全文
Cogent Biosciences(COGT)04-11 18:05
$Cogent Biosciences(COGT)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000926 Act: 33 Size: 1 KB 网页链接查看全文
Cogent Biosciences(COGT)04-03 06:25
$Cogent Biosciences(COGT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040496 Size: 5 KB 网页链接查看全文
Cogent Biosciences(COGT)04-02 06:25
$Cogent Biosciences(COGT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-039588 Size: 13 KB 网页链接查看全文
Cogent Biosciences(COGT)04-02 06:35
$Cogent Biosciences(COGT)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-083703 Act: 34 Size: 72 KB 网页链接查看全文
Cogent Biosciences(COGT)03-30 04:15
$Cogent Biosciences(COGT)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001193125-24-082065 Act: 33 Size: 382 KB 网页链接查看全文
Cogent Biosciences(COGT)03-22 20:35
$Cogent Biosciences(COGT)$ 8-K Current report, items 3.02, 5.03, and 9.01 Accession Number: 0001193125-24-074628 Act: 34 Size: 224 KB 网页链接查看全文
Cogent Biosciences(COGT)宣布已开始承销公开发行1.25亿美元的普通股。Cogent打算将此次发行的净收益用于与bezuclastinib和其他候选产品相关的开发、监管和商业准备活动,以及营运资金和一般公司用途。Jefferies、Piper Sandler& Co.和Gugge... 网页链接
$Cogent Biosciences(COGT)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-094760 Act: 34 Size: 728 KB 网页链接
$Cogent Biosciences(COGT)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000926 Act: 33 Size: 1 KB 网页链接
$Cogent Biosciences(COGT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040496 Size: 5 KB 网页链接
$Cogent Biosciences(COGT)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-083703 Act: 34 Size: 72 KB 网页链接
$Cogent Biosciences(COGT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-039588 Size: 13 KB 网页链接
$Cogent Biosciences(COGT)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001193125-24-082065 Act: 33 Size: 382 KB 网页链接
$Cogent Biosciences(COGT)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-078864 Act: 34 Size: 73 KB 网页链接
$Cogent Biosciences(COGT)$ 8-K Current report, items 3.02, 5.03, and 9.01 Accession Number: 0001193125-24-074628 Act: 34 Size: 224 KB 网页链接
$Cogent Biosciences(COGT)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-046239 Act: 33 Size: 69 KB 网页链接
$Cogent Biosciences(COGT)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-019770 Act: 34 Size: 16 MB 网页链接